Akros SCHK HK-U.S. Biotech Index

Q2 2026 earnings release and conference call on August 6, 2026, scheduled.

Q2 2026 earnings release and conference call on August 5, 2026; low impact is estimated as the announcement is a routine scheduling event, scheduled.

Amgen is scheduled to report its Q2 2026 financial results after the market closes on August 4, 2026; a high impact is estimated as quarterly earnings typically drive significant volatility, scheduled.

Q2 2026 earnings release and conference call scheduled. Earnings announcements typically trigger price movements of 5% or more, justifying a medium importance estimate scheduled.

Q2 2026 earnings release and conference call on 2026-08-04 scheduled.

AbbVie to announce second-quarter 2026 financial results before the market opens on 2026-07-31. High importance estimated due to potential for significant volatility following the report, scheduled.

As earnings releases typically result in a 5-10% price impact, the Q2 2026 earnings release and conference call on July 30, 2026, is scheduled.

Abbott reported Q2 2026 adjusted EPS of $1.31, beating estimates of ~$1.28, and raised its full-year 2026 adjusted EPS guidance to $5.45-$5.60. This guidance raise is estimated to cause a 5-9% price impact expected.

Positive results from the Phase 3 KEYNOTE-C93 trial for Keytruda in dMMR endometrial cancer patients are expected. High impact (>10%) estimated due to significant market expansion expected.

Johnson & Johnson reported Q2 2026 revenue of $25.3 billion (+6.6% YoY) and adjusted EPS of $2.90, beating analyst estimates. The company raised its full-year 2026 guidance for both sales and earnings.

The ex-dividend date for a quarterly cash dividend of $0.63 per share is July 15, 2026. Routine dividends typically have a price impact of 1-4% scheduled.